Sigma Healthcare Limited (SIG.AX) announced that, following preliminary discussions regarding the sale process of The Boots Group, its Board has elected to withdraw interest and cease discussions immediately. This decision follows Sigma's earlier announcement on 10 June 2026.
International growth remains one of Sigma's four key strategic pillars, and the Company continues to focus on driving expansion in its core offshore markets while exploring new opportunities. This includes the UK, where Sigma recently signed a Memorandum of Understanding with Greenlight Healthcare.
Sigma initially engaged in the Boots sale process given the unique opportunity it presented to accelerate UK expansion through the market-leading Boots brand and its extensive footprint. However, after a preliminary review, the Company concluded that such an acquisition would not align with its current strategic and capital investment objectives.
The Company remains confident in its established growth strategy, with a primary focus on the Australian market. Sigma will continue to assess opportunities, including potential acquisitions, across all markets that support its long-term strategy and deliver sustainable returns for shareholders.
SIG.AX was trading at A$2.84 up $0.20 or 7.58%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.